Boehringer Ingelheim Recognized As Global Top Employer for 2021

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, has been recognized for the very first time as a ‘Global Top Employer for 2021’ by the prestigious Top Employers Institute.

This year as a ‘Global Top Employer’, Boehringer Ingelheim joins the ranks of 16 other international organizations to receive this outstanding honor. While the organization has received awards on a country level for the past seven years, and in addition to the global award, the company has been further recognized as a ‘Top Employer’ across 27 country categories, spanning the European, Asia-Pacific, Latin-American and Middle Eastern regions. 

The independent Top Employers Institute certifies employers worldwide who wish to offer their employees excellent working conditions and support their development. Certification is based on a multi-level program to examine human resources management with detailed final feedback. Boehringer Ingelheim particularly impressed the certification board with its long-term strategic orientation, its modern management culture as well as strong employee communication practices, with its inclusive corporate culture also cited as a highlight. The jury found the organization’s ethical, inclusive approach to corporate decisions and a clear focus on the transfer and application of company values, to be highly commendable. 
“Receiving such a prestigious award for our efforts, despite the challenges faced in the past year, reflects the company focus on its employees as its main asset,” said Mohammed Al-Tawil, Country Managing Director and Head of Human Pharma META at Boehringer Ingelheim. “Strengthening our employee experience & capabilities is absolutely critical to our overarching strategy, as we rely on our teams to materialize our mission of creating value through innovation.”
A regional highlight coveted by Boehringer Ingelheim in the Middle East Region, was the ‘Top Employer’ recognition for its Saudi operation. “We are also delighted to have our Saudi offices recognized as a ‘Top Employer’ within their country division, stemming from the strong leadership, development and growth demonstrated by the team,” Tawil continued.

On her part, Birgit Giokalas, Human Resources Director for the region META shares, “We pride ourselves for our employee-centric approach to operations, as we make sure to offer our teams the support, infrastructure and corporate engagement required to succeed in the industry. An example of employee orientation that comes to mind are the areas around agile working methodologies. In this area, that has been in our focus for quite some time before COVID, among other, to ensure that during the pandemic, employees were able to quickly adapt their working styles to align with health protection requirements and to ensure business continuity. We have also worked on the future of work for the time after the pandemic to ensure the learnings and working style will continue and evolve in the years to come.  

For 135 years, Boehringer Ingelheim has been creating value through innovation for human and animal health, dedicating itself to a better world. It aims to meet this through excellent HR policies and people practices, covering domains such as people strategy, work environment, talent acquisition, learning, well-being, diversity, inclusion and more. The family business invests heavily in individual development opportunities through tailor-made education and training programs for all employees. This serves to enhance its existing progressive workplace culture promoting transparency, open communication and supportive forward-looking campaigns.

Boehringer Ingelheim will continue on its journey to implement further employee-focused initiatives, ensuring the growth, development and overarching wellbeing of its teams.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com . or in our annual report: http://annualreport.boehringer-ingelheim.com.

About Boehringer Ingelheim
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention. 
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros corresponded to 18.1 per cent of net sales. 
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards humankind and the environment. 
For more information please visit  https://www.mea.boehringer-ingelheim.com/

For more information, please contact:

Sara Shamel
Head of External Communications – META
Boehringer Ingelheim
T: +971 553258101
sara.shamel@boehringer-ingelheim.com